SGX393: New Drug Candidate That Knocks Out Resistant Form of Chronic Myeloid Leukemia (CML)
A new experimental drug has been found by Oregon Health & Science University (OHSU) Cancer Institute researchers to be effective against a highly resistant mutation in chronic myeloid leukemia (CML).
The said new drug candidate - SGX393 - has been found to inhibit most resistant mutations — including T315I — both in mouse models and in patient cells in laboratory studies.
This drug candidate could build on the legacy of Gleevec, which has been the gold standard for treating this leukemia and was developed by Brian Druker, M.D., director of the OHSU Cancer Institute.
Despite Gleevec’s success, some CML patients develop resistance to Gleevec, often due to mutations that interfere with drug binding.
The second-generation drugs Sprycel and Tasigna have been developed as largely successful treatments for Gleevec-resistant patients.
However, one mutation, termed T315I, is completely resistant to all three clinical CML drugs and is a frequent cause of relapse.
SGX393 was identified by SGX Pharmaceuticals Inc. — a biotechnology company focusing on cancer therapeutics – which after the above findings is worth pursuing further research of.
In the first half of 2008, SGX Pharmaceuticals, Inc.’s goal is to submit an Investigational New Drug (IND) application for SGX393 to the FDA.
Find more details from OHSU.
Tags: chronic-myeloid-leukemia-(CML), drug-candidate, Inc., OHSU, SGX-Pharmaceuticals, SGX393Related Stories
POSTED IN: on anti-cancer ingredients, on blood cancer
0 opinions for SGX393: New Drug Candidate That Knocks Out Resistant Form of Chronic Myeloid Leukemia (CML)
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: